Induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): Update of CT/RT 99/97

Abstract

7075 Background: In NSCLC simultaneous or induction radiochemotherapy is superior to chemo- or radiotherapy alone. Our study proves, weather after induction chemotherapy simultaneous radiochemotherapy is superior to radiotherapy alone. Methods: Patients (pts) with inoperable NSCLC IIIA/B are included. They get 2 cycles q3w of Paclitaxel 200mg/m2 and Carboplatinum AUC 6. If the tumor is not progressive the pts are randomized to radiotherapy alone (total dose at least 60 Gy per fraction) or simultaneous chemotherapy with weekly Paclitaxel 60mg/m2 and the same radiotherapy. Primary objective is survival; secondary endpoints are time to progression, response and toxicity. Results: Inclusion ended 05/02. The last follow-up was 11/03. As planned, 303 pts are included in the trial. 275 pts finished induction-therapy. 219 pts could be randomized: radiotherapy 115 pts, simultaneous radiochemotherapy 104 pts. Median survival is higher in the simultaneous arm: 18.67 months (95%CI 14.05–23.29) versus 14.1 months (95%...